Dr. Jianneng Li’s laboratory studies translational prostate cancer biology, with a focus on steroid metabolism, androgen receptor signaling, glucocorticoid receptor signaling, and mechanisms of therapeutic resistance. The lab investigates FDA-approved prostate cancer therapies, including abiraterone, enzalutamide, and PARP inhibitor-based regimens, while also studying investigational approaches such as supraphysiological androgen/bipolar androgen therapy. The Li Lab integrates clinically driven questions with mechanistic cancer biology to identify new therapeutic targets, improve the use of existing drugs, and develop strategies to overcome drug resistance and toxicity. Current work uses CRISPR/Cas9 knockout and activation screening, genome editing, live-cell imaging, small-molecule screening, computational prediction of protein-drug interactions, and collaborative translational models.
Post-doctoral Fellowship - Cleveland Clinic, Cleveland, OH 07/2021
Ph.D. - Fudan University, Shanghai, China 07/2013
